Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | proto oncogene serine:threonine protein kinase | 0.1647 | 1 | 1 |
Brugia malayi | Serine/threonine-protein kinase Pim-3 | 0.1647 | 1 | 1 |
Loa Loa (eye worm) | CAMK/CAMKL/PASK protein kinase | 0.108 | 0.628 | 0.4005 |
Echinococcus granulosus | proto oncogene serine:threonine protein kinase | 0.1647 | 1 | 1 |
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.0702 | 0.3795 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0702 | 0.3795 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0702 | 0.3795 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0702 | 0.3795 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0702 | 0.3795 | 0.5 |
Trypanosoma cruzi | casein kinase II, putative | 0.0702 | 0.3795 | 0.5 |
Trypanosoma brucei | Casein kinase II | 0.0702 | 0.3795 | 1 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.0702 | 0.3795 | 0.5 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.1647 | 1 | 1 |
Leishmania major | casein kinase II, putative | 0.0702 | 0.3795 | 0.5 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.1647 | 1 | 1 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.0702 | 0.3795 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0702 | 0.3795 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0702 | 0.3795 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0702 | 0.3795 | 0.5 |
Onchocerca volvulus | Serine\/threonine protein kinase homolog | 0.1647 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0702 | 0.3795 | 0.5 |
Entamoeba histolytica | casein kinase, putative | 0.0702 | 0.3795 | 0.5 |
Plasmodium vivax | unspecified product | 0.0702 | 0.3795 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1647 | 1 | 1 |
Giardia lamblia | Kinase, CMGC CK2 | 0.0702 | 0.3795 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.